Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors.

Kim YJ, Cubitt B, Chen E, Hull MV, Chatterjee AK, Cai Y, Kuhn JH, de la Torre JC.

Antiviral Res. 2019 Sep;169:104558. doi: 10.1016/j.antiviral.2019.104558. Epub 2019 Jul 11.

PMID:
31302150
2.

Interactome analysis of the lymphocytic choriomeningitis virus nucleoprotein in infected cells reveals ATPase Na+/K+ transporting subunit Alpha 1 and prohibitin as host-cell factors involved in the life cycle of mammarenaviruses.

Iwasaki M, Minder P, Caì Y, Kuhn JH, Yates JR 3rd, Torbett BE, de la Torre JC.

PLoS Pathog. 2018 Feb 20;14(2):e1006892. doi: 10.1371/journal.ppat.1006892. eCollection 2018 Feb.

3.
4.

A Proteomics Survey of Junín Virus Interactions with Human Proteins Reveals Host Factors Required for Arenavirus Replication.

Ziegler CM, Eisenhauer P, Kelly JA, Dang LN, Beganovic V, Bruce EA, King BR, Shirley DJ, Weir ME, Ballif BA, Botten J.

J Virol. 2018 Jan 30;92(4). pii: e01565-17. doi: 10.1128/JVI.01565-17. Print 2018 Feb 15.

5.

Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of Arenavirus Multiplication.

Ngo N, Henthorn KS, Cisneros MI, Cubitt B, Iwasaki M, de la Torre JC, Lama J.

J Virol. 2015 Nov;89(21):10924-33. doi: 10.1128/JVI.01587-15. Epub 2015 Aug 19. Erratum in: J Virol. 2016 Aug 26;90(18):8381.

6.

Sodium hydrogen exchangers contribute to arenavirus cell entry.

Iwasaki M, Ngo N, de la Torre JC.

J Virol. 2014 Jan;88(1):643-54. doi: 10.1128/JVI.02110-13. Epub 2013 Oct 30.

7.

Mining a Kröhnke Pyridine Library for Anti-Arenavirus Activity.

Miranda PO, Cubitt B, Jacob NT, Janda KD, de la Torre JC.

ACS Infect Dis. 2018 May 11;4(5):815-824. doi: 10.1021/acsinfecdis.7b00236. Epub 2018 Mar 1.

PMID:
29405696
8.

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.

Wang P, Liu Y, Zhang G, Wang S, Guo J, Cao J, Jia X, Zhang L, Xiao G, Wang W.

J Virol. 2018 Jul 31;92(16). pii: e00954-18. doi: 10.1128/JVI.00954-18. Print 2018 Aug 15.

9.

Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice.

Iwasaki M, Ng CT, Cubitt B, de la Torre JC.

J Virol. 2016 Oct 28;90(22):10102-10112. doi: 10.1128/JVI.01303-16. Print 2016 Nov 15.

10.

The PI3K/Akt pathway contributes to arenavirus budding.

Urata S, Ngo N, de la Torre JC.

J Virol. 2012 Apr;86(8):4578-85. doi: 10.1128/JVI.06604-11. Epub 2012 Feb 15.

11.

General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.

Iwasaki M, Ngo N, Cubitt B, Teijaro JR, de la Torre JC.

J Virol. 2015 Dec;89(23):12166-77. doi: 10.1128/JVI.02075-15. Epub 2015 Sep 23.

12.

Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis.

Oppliger J, Torriani G, Herrador A, Kunz S.

J Virol. 2016 Jun 24;90(14):6412-6429. doi: 10.1128/JVI.00257-16. Print 2016 Jul 15.

13.

Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses.

de la Torre JC.

Ann N Y Acad Sci. 2009 Sep;1171 Suppl 1:E57-64. doi: 10.1111/j.1749-6632.2009.05048.x.

PMID:
19751403
14.

A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.

Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, Alexander J, Kotturi MF, Sette A, Buchmeier MJ.

J Virol. 2010 Oct;84(19):9947-56. doi: 10.1128/JVI.00672-10. Epub 2010 Jul 28.

15.

Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines.

Martinez-Sobrido L, de la Torre JC.

Expert Rev Vaccines. 2016 Sep;15(9):1113-21. doi: 10.1080/14760584.2016.1182024. Epub 2016 May 13. Review.

16.

A Map of the Arenavirus Nucleoprotein-Host Protein Interactome Reveals that Junín Virus Selectively Impairs the Antiviral Activity of Double-Stranded RNA-Activated Protein Kinase (PKR).

King BR, Hershkowitz D, Eisenhauer PL, Weir ME, Ziegler CM, Russo J, Bruce EA, Ballif BA, Botten J.

J Virol. 2017 Jul 12;91(15). pii: e00763-17. doi: 10.1128/JVI.00763-17. Print 2017 Aug 1.

17.

Review of Mammarenavirus Biology and Replication.

Hallam SJ, Koma T, Maruyama J, Paessler S.

Front Microbiol. 2018 Aug 3;9:1751. doi: 10.3389/fmicb.2018.01751. eCollection 2018.

18.

Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.

Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, Schmaljohn CS, Polyak SJ, White JM.

J Virol. 2019 Apr 3;93(8). pii: e02185-18. doi: 10.1128/JVI.02185-18. Print 2019 Apr 15.

19.

The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis.

Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, Love MS, Hull MV, Kuhen KL, Woods AK, Joseph SB, Petrassi HM, McNamara CW, Tremblay MS, Su AI, Schultz PG, Chatterjee AK.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10750-10755. doi: 10.1073/pnas.1810137115. Epub 2018 Oct 3.

20.

Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays.

Caì Y, Iwasaki M, Beitzel BF, Yú S, Postnikova EN, Cubitt B, DeWald LE, Radoshitzky SR, Bollinger L, Jahrling PB, Palacios GF, de la Torre JC, Kuhn JH.

Viruses. 2018 Nov 20;10(11). pii: E655. doi: 10.3390/v10110655.

Supplemental Content

Support Center